Spondyloarthropathies News

PHILADELPHIA — Patients who started TNF inhibitors earlier in their ankylosing spondyloarthritis disease course, vs. no initiation, have a higher risk for cardiovascular events, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Making sense of real-world data and black-box warnings associated with Janus kinase inhibitors can be challenging for rheumatologists hoping to prescribe these medications, according to a presenter at ACR Convergence 2022.

PHILADELPHIA — A daily glucocorticoid dose higher than 2.5 mg may lead to irreversible bone mineral density loss regardless of intervention with osteoporosis medications, according to data presented at ACR Convergence 2022.

Among women with spondyloarthritis, those who are of older age and use of NSAIDs during preconception demonstrate longer time to conception, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Patients who switched from one infliximab biosimilar to another experienced comparable treatment retention rates, according to data presented at ACR Convergence 2022.

Axial spondyloarthritis management should be guided by a predetermined treatment target, according to new recommendations published by the Assessment of Spondyloarthritis international Society and EULAR.

SAN DIEGO — Although current American College of Rheumatology guidelines eschew treat-to-target for axial spondyloarthritis, “aggressive treatment” is still needed to manage the disease, noted a speaker here.

The FDA has approved upadacitinib for the treatment of non-radiographic axial spondyloarthritis, marking the sixth indication for the therapy, according to a press release from AbbVie.

Patients with immune-mediated inflammatory diseases demonstrate a lower, less durable COVID-19 vaccine response and are at risk for losing humoral immune protection, according to data published in The Lancet Rheumatology.

Upadacitinib demonstrated significant improvements in patients with non-radiographic axial spondyloarthritis when compared with a placebo at 14 weeks, according to data published in The Lancet.